Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/18/24
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common StockGlobeNewsWire • 10/17/24
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society CongressGlobeNewsWire • 10/11/24
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 10/09/24
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?Zacks Investment Research • 10/08/24
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society CongressGlobeNewsWire • 10/04/24
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?Zacks Investment Research • 09/24/24
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024GlobeNewsWire • 09/23/24
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 09/17/24
Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesGlobeNewsWire • 09/06/24
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/07/24
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 06/25/24
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program GoingSeeking Alpha • 06/17/24
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayGlobeNewsWire • 06/11/24